Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma
Executive Summary
Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.
You may also be interested in...
Executives On The Move: Changes At Pieris, Skye Bioscience And More
New leaders in regulatory affairs and R&D at Skye Bioscience and promotions at Pieris Pharmaceuticals are among recent executive changes in the industry. Meanwhile, new directors were appointed at Summit Therapeutics, Ovid Therapeutics and Spero Therapeutics, among others.
Pipeline Watch: Phase III Readouts in Fabry's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Trial Starts And COVID-19 Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.